Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J Van den bent; Brigitta Baumert; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Marc Sanson; Alba Ariela Brandes; Paul M Clement; Jean Francais Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; David G Brachman; Walter Taal; Roberta Rudà; Michael Weller; Catherine Mcbain; Jaap Reijneveld; Roelien H Enting; Damien C Weber; Thierry Lesimple; Susan Clenton; Anja Gijtenbeek; Sarah Pascoe; Ulrich Herrlinger; Peter Hau; Frederic Dhermain; Irene Van heuvel; Roger Stupp; Ken Aldape; Robert B Jenkins; Hendrikus Jan Dubbink; Winand N M Dinjens; Pieter Wesseling; Sarah Nuyens; Vassilis Golfinopoulos; Thierry Gorlia; Wolfgang Wick; Johan M Kros

doi:10.1016/S0140-6736(17)31442-3

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J Van den bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason, Helen Wheeler, Olivier L Chinot, Sanjeev Gill, Matthew Griffin, David G Brachman, Walter Taal, Roberta Rudà, Michael Weller, Catherine Mcbain, Jaap ReijneveldRoelien H Enting, Damien C Weber, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Sarah Pascoe, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Irene Van heuvel, Roger Stupp, Ken Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Winand N M Dinjens, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Wolfgang Wick, Johan M Kros

Deanery of Molecular, Genetic and Population Health Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1645-1653
Journal	The Lancet
Volume	390
Issue number	10103
DOIs	https://doi.org/10.1016/S0140-6736(17)31442-3
Publication status	Published - 1 Oct 2017

Access to Document

10.1016/S0140-6736(17)31442-3

https://linkinghub.elsevier.com/retrieve/pii/S0140673617314423

Cite this

Van den bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Brachman, D. G., Taal, W., Rudà, R., Weller, M., Mcbain, C., ... Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet, 390(10103), 1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3

@article{aec58e825d2c4b26bff24c22cc9c662c,

title = "Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study",

author = "{Van den bent}, {Martin J} and Brigitta Baumert and Erridge, {Sara C} and Vogelbaum, {Michael A} and Nowak, {Anna K} and Marc Sanson and Brandes, {Alba Ariela} and Clement, {Paul M} and Baurain, {Jean Francais} and Mason, {Warren P} and Helen Wheeler and Chinot, {Olivier L} and Sanjeev Gill and Matthew Griffin and Brachman, {David G} and Walter Taal and Roberta Rud{\`a} and Michael Weller and Catherine Mcbain and Jaap Reijneveld and Enting, {Roelien H} and Weber, {Damien C} and Thierry Lesimple and Susan Clenton and Anja Gijtenbeek and Sarah Pascoe and Ulrich Herrlinger and Peter Hau and Frederic Dhermain and {Van heuvel}, Irene and Roger Stupp and Ken Aldape and Jenkins, {Robert B} and Dubbink, {Hendrikus Jan} and Dinjens, {Winand N M} and Pieter Wesseling and Sarah Nuyens and Vassilis Golfinopoulos and Thierry Gorlia and Wolfgang Wick and Kros, {Johan M}",

year = "2017",

month = oct,

day = "1",

doi = "10.1016/S0140-6736(17)31442-3",

language = "English",

volume = "390",

pages = "1645--1653",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10103",

}

Van den bent, MJ, Baumert, B, Erridge, SC, Vogelbaum, MA, Nowak, AK, Sanson, M, Brandes, AA, Clement, PM, Baurain, JF, Mason, WP, Wheeler, H, Chinot, OL, Gill, S, Griffin, M, Brachman, DG, Taal, W, Rudà, R, Weller, M, Mcbain, C, Reijneveld, J, Enting, RH, Weber, DC, Lesimple, T, Clenton, S, Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, Van heuvel, I, Stupp, R, Aldape, K, Jenkins, RB, Dubbink, HJ, Dinjens, WNM, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, JM 2017, 'Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study', The Lancet, vol. 390, no. 10103, pp. 1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. / Van den bent, Martin J; Baumert, Brigitta; Erridge, Sara C et al.
In: The Lancet, Vol. 390, No. 10103, 01.10.2017, p. 1645-1653.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

AU - Van den bent, Martin J

AU - Baumert, Brigitta

AU - Erridge, Sara C

AU - Vogelbaum, Michael A

AU - Nowak, Anna K

AU - Sanson, Marc

AU - Brandes, Alba Ariela

AU - Clement, Paul M

AU - Baurain, Jean Francais

AU - Mason, Warren P

AU - Wheeler, Helen

AU - Chinot, Olivier L

AU - Gill, Sanjeev

AU - Griffin, Matthew

AU - Brachman, David G

AU - Taal, Walter

AU - Rudà, Roberta

AU - Weller, Michael

AU - Mcbain, Catherine

AU - Reijneveld, Jaap

AU - Enting, Roelien H

AU - Weber, Damien C

AU - Lesimple, Thierry

AU - Clenton, Susan

AU - Gijtenbeek, Anja

AU - Pascoe, Sarah

AU - Herrlinger, Ulrich

AU - Hau, Peter

AU - Dhermain, Frederic

AU - Van heuvel, Irene

AU - Stupp, Roger

AU - Aldape, Ken

AU - Jenkins, Robert B

AU - Dubbink, Hendrikus Jan

AU - Dinjens, Winand N M

AU - Wesseling, Pieter

AU - Nuyens, Sarah

AU - Golfinopoulos, Vassilis

AU - Gorlia, Thierry

AU - Wick, Wolfgang

AU - Kros, Johan M

PY - 2017/10/1

Y1 - 2017/10/1

U2 - 10.1016/S0140-6736(17)31442-3

DO - 10.1016/S0140-6736(17)31442-3

M3 - Article

SN - 0140-6736

VL - 390

SP - 1645

EP - 1653

JO - The Lancet

JF - The Lancet

IS - 10103

ER -

Van den bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet. 2017 Oct 1;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3